Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Piera Capranzano & Dominick J. Angiolillo. (2021) Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy 19:6, pages 519-535.
Read now
Read now
Chang Hoon Lee, Francesco Franchi & Dominick J. Angiolillo. (2020) Clopidogrel drug interactions: a review of the evidence and clinical implications. Expert Opinion on Drug Metabolism & Toxicology 16:11, pages 1079-1096.
Read now
Read now
Piotr Adamski, Urszula Adamska, Małgorzata Ostrowska, Marek Koziński & Jacek Kubica. (2016) New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opinion on Pharmacotherapy 17:17, pages 2291-2306.
Read now
Read now
Erik L Grove, Morten Würtz, Mark R Thomas & Steen Dalby Kristensen. (2015) Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy 16:14, pages 2133-2147.
Read now
Read now
Jacek Kubica, Marek Kozinski, Eliano Pio Navarese, Udaya Tantry, Aldona Kubica, Jolanta Maria Siller-Matula, Young-Hoon Jeong, Tomasz Fabiszak, Anna Andruszkiewicz & Paul Alfred Gurbel. (2014) Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Current Medical Research and Opinion 30:5, pages 813-828.
Read now
Read now
Francesco Franchi, Fabiana Rollini, Ana Muñiz-Lozano, Jung Rae Cho & Dominick J Angiolillo. (2013) Cangrelor: a review on pharmacology and clinical trial development. Expert Review of Cardiovascular Therapy 11:10, pages 1279-1291.
Read now
Read now
Deepu Alexander & Allen Jeremias. (2011) Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opinion on Investigational Drugs 20:6, pages 849-857.
Read now
Read now
Masafumi Ueno, José Luis Ferreiro & Dominick J Angiolillo. (2010) Update on the clinical development of cangrelor. Expert Review of Cardiovascular Therapy 8:8, pages 1069-1077.
Read now
Read now
Articles from other publishers (66)
Vitoria Guero Korb, Iago Carvalho Schultz, Liziane Raquel Beckenkamp & Márcia Rosângela Wink. (2023) A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19. International Journal of Molecular Sciences 24:9, pages 7865.
Crossref
Crossref
Muhammad Abubakar, Saud Raza, Khawaja Mushammar Hassan, Izzah Javed, Khawaja Momal Hassan, Fiza Farrukh, Khawaja Muthammir Hassan & Muhammad Ahmad Faraz. (2023) Efficacy, Safety, and Role of Antiplatelet Drugs in the Management of Acute Coronary Syndrome: A Comprehensive Review of Literature. Cureus.
Crossref
Crossref
Akhila Dandamudi, William Seibel, Benjamin Tourdot, Jose A. Cancelas, Huzoor Akbar & Yi Zheng. (2023) Structure–Activity Relationship Analysis of Rhosin, a RhoA GTPase Inhibitor, Reveals a New Class of Antiplatelet Agents. International Journal of Molecular Sciences 24:4, pages 4167.
Crossref
Crossref
Shunlai Li, Yajing Ren, Qiwen He, Yongji Wei & Hongguang Du. (2022)
Synthesis of novel purine derivatives: Antiplatelet aggregation activity evaluation and
3D‐QSAR
analysis
. Journal of Heterocyclic Chemistry 59:11, pages 2016-2024.
Crossref
Crossref
Ahmed O. Mohammed, Mazin I. Abo-Idrees, Alaa A. Makki, Walaa Ibraheem & Abdulrahim A. Alzain. (2022) Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MM-GBSA calculations and molecular dynamics. Structural Chemistry 33:5, pages 1553-1567.
Crossref
Crossref
Leonardo De Luca, Paolo Calabrò, Fabio Chirillo, Cristina Rolfo, Alberto Menozzi, Piera Capranzano, Maurizio Menichelli, Elisa Nicolini, Ciro Mauro, Carlo Trani, Francesco Versaci, Fabrizio Tomai, Giuseppe Musumeci, Carlo Di Mario, Martino Pepe, Sergio Berti, Carlo Cernetti, Plinio Cirillo, Diego Maffeo, Giuseppe Talanas, Marco Ferlini, Marco Contarini, Valerio Lanzilotti, Marino Scherillo, Giuseppe Tarantini, Simone Muraglia, Roberta Rossini & Leonardo Bolognese. (2022) Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. Clinical Cardiology 45:9, pages 913-920.
Crossref
Crossref
Piera Capranzano & Dominick J. Angiolillo. 2022. Interventional Cardiology. Interventional Cardiology
407
419
.
A. Selvarajah, A. H. Tavenier, W. L. Bor, V. Houben, S. Rasoul, E. Kaplan, K. Teeuwen, S. H. Hofma, E. Lipsic, G. Amoroso, M. A. H. van Leeuwen, J. M. ten Berg, A. W. J. van ‘t Hof & R. S. Hermanides. (2021) Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry. BMC Cardiovascular Disorders 21:1.
Crossref
Crossref
Devin N. Holden, Pouya Entezami, Maximilian C. Bush, Nicholas C. Field, Alexandra R. Paul, Alan S. Boulos, Junichi Yamamoto & John C. Dalfino. (2021) Characterization of antiplatelet response to low‐dose cangrelor utilizing platelet function testing in neuroendovascular patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:10, pages 811-819.
Crossref
Crossref
Leonardo De Luca, Philippe Gabriel Steg, Deepak L. Bhatt, Davide Capodanno & Dominick J. Angiolillo. (2021) Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. Journal of the American Heart Association 10:13.
Crossref
Crossref
Manisha Prajapat, Nishant Shekhar, Phulen Sarma, Pramod Avti, Sanjay Singh, Hardeep Kaur, Anusuya Bhattacharyya, Subodh Kumar, Saurabh Sharma, Ajay Prakash & Bikash Medhi. (2020) Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. Journal of Molecular Graphics and Modelling 101, pages 107716.
Crossref
Crossref
Giuseppe GargiuloGiovanni EspositoMarisa AvvedimentoMichael NaglerPietro MinuzGianluca CampoFelice GragnanoNegar ManavifarRaffaele PiccoloMatteo TebaldiPlinio CirilloLukas HunzikerPascal VranckxSergio LeonardiDik HegStephan WindeckerMarco Valgimigli. (2020) Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation 142:5, pages 441-454.
Crossref
Crossref
Emmanuelle Scala, Christiane Gerschheimer, Francisco J. Gomez, Lorenzo Alberio & Carlo Marcucci. (2020) Potential and Limitations of the New P2Y12 Inhibitor, Cangrelor, in Preventing Heparin-Induced Platelet Aggregation During Cardiac Surgery: An In Vitro Study. Anesthesia & Analgesia 131:2, pages 622-630.
Crossref
Crossref
Shunlai Li, Cheng Zhou, Mingwu Yu, Qiwen He & Hongguang Du. (2020) Synthesis, anti‐platelet aggregation activity evaluation and structure–activity relationships of a series of novel purine derivatives. Journal of Heterocyclic Chemistry 57:7, pages 2889-2903.
Crossref
Crossref
Shunlai Li, XueFeng Bao, Chenghu Lu, Chaorui Ren, Guocheng Liu & Hongguang Du. (2020) Essential Structural Profile of Novel Adenosine Derivatives as Antiplatelet Aggregation Inhibitors Based on 3D-QSAR Analysis Using CoMFA, CoMSIA, and SOMFA. Russian Journal of Bioorganic Chemistry 46:3, pages 448-457.
Crossref
Crossref
Michelle M. Schreuder, Ricardo Badal, Eric Boersma, Maryam Kavousi, Jolien Roos‐Hesselink, Jorie Versmissen, Loes E. Visser & Jeanine E. Roeters van Lennep. (2020)
Efficacy and Safety of High Potent P2Y
12
Inhibitors Prasugrel and Ticagrelor in Patients With Coronary Heart Disease Treated With Dual Antiplatelet Therapy: A Sex‐Specific Systematic Review and Meta‐Analysis
. Journal of the American Heart Association 9:4.
Crossref
Crossref
Tauseef Akhtar, Dhrubajyoti Bandyopadhyay, Raktim K. Ghosh, Wilbert S. Aronow, Carl J. Lavie & Neha Yadav. (2020) Advances in the Pharmacogenomics of Antiplatelet Therapy. American Journal of Therapeutics 27:5, pages e477-e484.
Crossref
Crossref
Bassel Bou Dargham, Amutharani Baskar, Ishita Tejani, Zhonghao Cui, Siddarth Chauhan, John Sum-Ping, Rick A. Weideman & Subhash Banerjee. (2019) Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention. Cardiovascular Revascularization Medicine 20:9, pages 805-811.
Crossref
Crossref
Alexander M. Girgis, Eugene Golts, Doug Humber & Dalia A. Banks. (2019) Successful Use of Cangrelor and Heparin for Cardiopulmonary Bypass in a Patient With Heparin-Induced Thrombocytopenia and End-Stage Renal Disease: A Case Report. A&A Practice 13:1, pages 10-12.
Crossref
Crossref
Fabrizio Pertusati, Michaela Serpi & Elisa Pileggi. 2019. Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals. Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals
141
180
.
Daniel R. Mangels, Ashwin Nathan, Sony Tuteja, Jay Giri & Taisei Kobayashi. (2018) Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes. Current Treatment Options in Cardiovascular Medicine 20:2.
Crossref
Crossref
Taylor C. Bazemore, Michael G. Nanna & Sunil V. Rao. (2017) Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina. Journal of Thrombosis and Thrombolysis 44:3, pages 303-315.
Crossref
Crossref
Piera Capranzano & Dominick J. Angiolillo. 2017. Interventional Cardiology. Interventional Cardiology
377
388
.
Christian Weber, Lina Badimon, Francois Mach & Emiel P. C. van der Vorst. (2017) Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future. Thrombosis and Haemostasis 117:07, pages 1258-1264.
Crossref
Crossref
Willibald Hochholzer, Pascal Kleiner, Iris Younas, Christian M. Valina, Nikolaus Löffelhardt, Michael Amann, Timo Bömicke, Miroslaw Ferenc, Dieter Hauschke, Dietmar Trenk, Franz-Josef Neumann & Christian Stratz. (2017) Randomized Comparison of Oral P2Y12-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor. JACC: Cardiovascular Interventions 10:2, pages 121-129.
Crossref
Crossref
Lisa Gross, Dániel Aradi & Dirk Sibbing. 2017. Platelets in Thrombotic and Non-Thrombotic Disorders. Platelets in Thrombotic and Non-Thrombotic Disorders
1253
1267
.
Ana Lucrecia Marcano & José Luis Ferreiro. (2016) Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor. Current Atherosclerosis Reports 18:11.
Crossref
Crossref
Piera Capranzano, Davide Capodanno, Chiara Bucciarelli-Ducci, Giuseppe Gargiulo, Claudia Tamburino, Bruno Francaviglia, Yohei Ohno, Alessio La Manna, Salemi Antonella, Guilherme F Attizzani, Dominick J Angiolillo & Corrado Tamburino. (2016) Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care 5:5, pages 475-486.
Crossref
Crossref
Ana Afonso, Gil Marques, Ana Gonçalves, Pedro Barroso, Antonio Gonzalez, Hugo Rodrigues & Maria José Ferreira. (2016) A terapêutica antitrombótica: atual e em desenvolvimento. Angiologia e Cirurgia Vascular 12:3, pages 170-179.
Crossref
Crossref
Willibald Hochholzer, Michael Amann, Alexander Titov, Iris Younas, Nikolaus Löffelhardt, Florian Riede, Clemens Potocnik, Christian Stratz, Dieter Hauschke, Dietmar Trenk, Franz-Josef Neumann & Christian M. Valina. (2016) Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention. JACC: Cardiovascular Interventions 9:3, pages 219-227.
Crossref
Crossref
Nicholas Bowen & Shaker A. Mousa. 2016. Anticoagulation and Hemostasis in Neurosurgery. Anticoagulation and Hemostasis in Neurosurgery
65
89
.
Thibault Lhermusier, Nevin C. Baker & Ron Waksman. (2015) Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Cangrelor. The American Journal of Cardiology 115:8, pages 1154-1161.
Crossref
Crossref
Michael Luna & Elizabeth M. Holper. (2015) Use of Novel Antiplatelet Agents in Acute Coronary Syndromes. Current Atherosclerosis Reports 17:3.
Crossref
Crossref
Jeremiah P. DeptaDeepak L. Bhatt. (2015) New Approaches to Inhibiting Platelets and Coagulation. Annual Review of Pharmacology and Toxicology 55:1, pages 373-397.
Crossref
Crossref
Ioannis V. Ntalas, Haralampos J. Milionis, Anastazia A. Kei, Kallirroi I. Kalantzi & John A. Goudevenos. (2013) Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease. Angiology 65:6, pages 473-490.
Crossref
Crossref
M. Sousa-Uva, R. Storey, K. Huber, V. Falk, A. F. Leite-Moreira, J. Amour, N. A.- Attar, R. Ascione, D. Taggart & J.-P. Collet. (2014) Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. European Heart Journal 35:23, pages 1510-1514.
Crossref
Crossref
Dimitrios AlexopoulosGeorge MakrisIoanna XanthopoulouSotirios PatsilinakosSpyridon DeftereosVassilios GkizasAngelos PerperisStavros KaranikasChristos AngelidisGrigorios TsigkasNikolaos KoutsogiannisGeorge HahalisPeriklis Davlouros. (2014) Onset of Antiplatelet Action With High (100 mg) Versus Standard (60 mg) Loading Dose of Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions 7:2, pages 233-239.
Crossref
Crossref
Fabiana Rollini, Francesco Franchi, Antonio Tello-Montoliu, Ronakkumar Patel, Andrew Darlington, José Luis Ferreiro, Jung Rae Cho, Ana Muñiz-Lozano, Bhaloo Desai, Martin M. Zenni, Luis A. Guzman, Theodore A. Bass & Dominick J. Angiolillo. (2014) Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor–Mediated Signaling in Prasugrel-Treated Patients. JACC: Cardiovascular Interventions 7:4, pages 426-434.
Crossref
Crossref
Nuccia Morici, Lorenzo Moja, Valentina Rosato, Alice Sacco, Antonio Mafrici, Silvio Klugmann, Maurizio D’Urbano, Carlo La Vecchia, Stefano De Servi & Stefano Savonitto. (2014) Bridge with intravenous antiplatelet therapy during temporary withdrawal of oral agents for surgical procedures: a systematic review. Internal and Emergency Medicine 9:2, pages 225-235.
Crossref
Crossref
Antonio Tello-Montoliu & Dominick Angiolillo. 2014. Handbook of Personalized Medicine. Handbook of Personalized Medicine
1117
1170
.
Victor L. Serebruany, Alex N. Pokov, Seth D. Fortmann & James J. DiNicolantonio. (2017) Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: The cangrelor efficacy challenge. Thrombosis and Haemostasis 111:01, pages 3-7.
Crossref
Crossref
Victor L. Serebruany, Dirk Sibbing & James J. DiNicolantonio. (2014) Dyspnea and Reversibility of Antiplatelet Agents: Ticagrelor, Elinogrel, Cangrelor, and Beyond. Cardiology 127:1, pages 20-24.
Crossref
Crossref
Alberto Cecconi, David Vivas & Antonio Fernández-Ortiz. (2014) Nuevas evidencias sobre la antiagregación para el síndrome coronario agudo sin elevación del ST. Revista Española de Cardiología Suplementos 14, pages 18-23.
Crossref
Crossref
Sergio Leonardi, Marco Ferlini, Marcello Marino & Luigi Oltrona Visconti. (2013) The Fall and Rise of Cangrelor. Drug Development Research 74:8, pages 526-532.
Crossref
Crossref
Judy W. M. Cheng. (2013) Updates in Antiplatelet Agents Used in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology and Therapeutics 18:6, pages 514-524.
Crossref
Crossref
Victor L. Serebruany, Daniel Aradi, Moo Hyun Kim & Dirk Sibbing. (2013) Cangrelor infusion is associated with an increased risk for bleeding: Meta-analysis of randomized trials. International Journal of Cardiology 169:3, pages 225-228.
Crossref
Crossref
M. Ungerer & G. Münch. (2013) Novel antiplatelet drugs in clinical development. Thrombosis and Haemostasis 110:5, pages 868-875.
Crossref
Crossref
Piera Capranzano & Dominick J. Angiolillo. (2013) Basics of Antithrombotic Therapy for Cardiovascular Disease. Interventional Cardiology Clinics 2:4, pages 499-513.
Crossref
Crossref
Piera Capranzano, Corrado Tamburino & George D. Dangas. (2013) Combination Antithrombotic Management of STEMI with Pharmacoinvasive Strategy, Primary PCI, or Rescue PCI. Interventional Cardiology Clinics 2:4, pages 573-583.
Crossref
Crossref
D. Capodanno, J.L. Ferreiro & D.J. Angiolillo. (2013) Antiplatelet therapy: new pharmacological agents and changing paradigms. Journal of Thrombosis and Haemostasis 11, pages 316-329.
Crossref
Crossref
Fabiana Rollini, Francesco Franchi, Ana Muñiz-Lozano & Dominick J Angiolillo. (2013) Platelet Function Profiles in Patients with Diabetes Mellitus. Journal of Cardiovascular Translational Research 6:3, pages 329-345.
Crossref
Crossref
José L. Ferreiro, Masafumi Ueno, Antonio Tello-Montoliu, Salvatore D. Tomasello, Davide Capodanno, Piera Capranzano, Kodlipet Dharmashankar, Andrew Darlington, Bhaloo Desai, Fabiana Rollini, Luis A. Guzman, Theodore A. Bass & Dominick J. Angiolillo. (2012) Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. Journal of Thrombosis and Thrombolysis 35:2, pages 155-164.
Crossref
Crossref
John S. Schroeder, William H. Frishman, John D. Parker, Dominick J. Angiolillo, Christopher Woods & Benjamin M. Scirica. 2013. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease
83
130
.
Dominick J. Angiolillo. (2012) The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. Drugs 72:16, pages 2087-2116.
Crossref
Crossref
Dominick J. Angiolillo, David J. Schneider, Deepak L. Bhatt, William J. French, Matthew J. Price, Jorge F. Saucedo, Tamaz Shaburishvili, Kurt Huber, Jayne Prats, Tiepu Liu, Robert A. Harrington & Richard C. Becker. (2012) Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. Journal of Thrombosis and Thrombolysis 34:1, pages 44-55.
Crossref
Crossref
José Luis FerreiroDominick J. Angiolillo. (2012) New Directions in Antiplatelet Therapy. Circulation: Cardiovascular Interventions 5:3, pages 433-445.
Crossref
Crossref
Craig R. Narins. 2012. Textbook of Interventional Cardiology. Textbook of Interventional Cardiology
75
84
.
Isabell Bernlochner & Dirk Sibbing. 2012. Antiplatelet Agents. Antiplatelet Agents
165
198
.
Ming Hao, Yan Li, Yonghua Wang, Yulian Yan & Shuwei Zhang. (2011)
Combined 3D-QSAR, Molecular Docking, and Molecular Dynamics Study on Piperazinyl-Glutamate-Pyridines/Pyrimidines as Potent P2Y
12
Antagonists for Inhibition of Platelet Aggregation
. Journal of Chemical Information and Modeling 51:10, pages 2560-2572.
Crossref
Crossref
Béatrice Hechler & Christian Gachet. (2011) P2 receptors and platelet function. Purinergic Signalling 7:3, pages 293-303.
Crossref
Crossref
Antonio Tello-Montoliu, Masafumi Ueno & Dominick J Angiolillo. (2011) Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Future Cardiology 7:3, pages 381-402.
Crossref
Crossref
Masafumi Ueno, Murali Kodali, Antonio Tello-Montoliu & Dominick Joseph Angiolillo. (2011) Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis 18:6, pages 431-442.
Crossref
Crossref
José Luis Ferreiro, Ángel R Cequier & Dominick J Angiolillo. (2010) Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. Diabetes and Vascular Disease Research 7:4, pages 274-288.
Crossref
Crossref
David Vivas & Dominick J. Angiolillo. (2010) Platelet P2Y12 Receptor Inhibition. American Journal Cardiovascular Drugs 10:4, pages 217-226.
Crossref
Crossref
Masafumi Ueno, Sunil V Rao & Dominick J Angiolillo. (2010) Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiology 6:4, pages 445-453.
Crossref
Crossref
Dominick J. Angiolillo, Masafumi Ueno & Shinya Goto. (2010) Basic Principles of Platelet Biology and Clinical Implications. Circulation Journal 74:4, pages 597-607.
Crossref
Crossref